

ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

Association of alpha-1 antitrypsin level and lung function in patients with chronic obstructive pulmonary disease

Danielius Serapinas¹, Ruta Nutautiene², Ruta Pukinskaite¹, Daiva Bartkeviciene³, Diana Barkauskiene⁴, Raimundas Sakalauskas⁴

¹Mykolas Romeris University, Vilnius, Lithuania;

²Kaunas State Hospital, Kaunas, Lithuania;

³Vilnius University, Faculty of Medicine, Department of Obstetrics and Gynecology, Vilnius, Lithuania;

⁴Lithuanian University of Health Sciences, Medical Academy, Department of Pulmonology and Immunology, Kaunas, Lithuania



SUMMARY

Introduction/Objective Alpha-1 antitrypsin deficiency is a well established inherited risk factor for chronic obstructive pulmonary disease (COPD); however, alpha-1 antitrypsin level may result in different lung function reduction.

The aim of our study was to evaluate possible associations of alpha-1 antitrypsin level and lung function in COPD patients with different alpha-1 antitrypsin phenotypes.

Methods Serum alpha-1 antitrypsin concentration from patients (n = 1,167) with COPD, defined according to the GOLD criteria, were analyzed by nephelometry, and alpha-1 antitrypsin phenotype was determined by means of isoelectric-focusing.

Results In COPD patients without alpha-1 antitrypsin deficiency (MM), a significant negative association of lung function (FEV₁) with serum alpha-1 antitrypsin (r = -0.511; p < 0.05) and C-reactive protein (CRP) concentrations (r = -0.583; p < 0.05) was detected; moreover, the level of alpha-1 antitrypsin positively correlated with CRP concentration (r = 0.667; p < 0.05).

Conclusions In patients without alpha-1 antitrypsin deficiency, detected negative association of alpha-1 antitrypsin level with FEV₁ and positive association with the CRP level defined the importance of alpha-1 antitrypsin for lung function in COPD patients.

Keywords: chronic obstructive pulmonary disease; alpha-1 antitrypsin; lung function

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a prevalent and costly disease characterized by a progressive airflow limitation, related to an abnormal inflammatory response of the lung to long-term tobacco smoke exposure or inhalation of toxic gases [1]. Lung inflammation is further amplified by oxidative stress and proteolytic damage by proteinases [2, 3]. There is increasing data of systemic inflammation in patients with COPD [4–7]. Thus, the changes of inflammatory markers can be evaluated in the lungs and in serum affecting gas diffusion and lung function [3, 4, 5].

The best described inherited risk factor for COPD is alpha-1 antitrypsin (AAT) deficiency. Primary AAT function is to inhibit neutrophil elastase [6, 7, 8]. In severe AAT deficiency, anti-elastase protection in the lung interstitium and alveolar zone is decreased to about 15–20% of normal limits, similar to the decrease in serum levels [9–12]. The majority of AAT deficiency cases (96%) have a PI*ZZ phenotype. The remaining cases belong to PI*SZ, PI*MZ, and other especially rare deficiency phenotypes [9]. AAT is a rare disorder because it is under-

diagnosed worldwide; more than 80% of AAT deficiency patients remain unrecognized [10].

The potential role of systemic inflammation in the pathogenesis of lung function decline in COPD patients with different AAT phenotypes has not yet been well established.

The aim of our study was to evaluate possible associations of AAT level and lung function parameters in patients with COPD with different AAT phenotypes.

METHODS

Sample sources and subject selection

The study content was approved by the Lithuanian Bioethics Committee. A total of 1,167 patients with COPD, who gave their informed consent, were included in the study at the Department of Pulmonology and Immunology, Medical Academy, LUHS.

Only patients who met the GOLD spirometric criteria for COPD: 1) ratio of post-bronchodilator forced expiratory volume in one second (FEV₁) to forced vital capacity (FVC) less than 0.7, and 2) FEV₁ less than 80% of the predicted

Примљено • Received:
August 9, 2016

Ревизија • Revised:
July 17, 2017

Прихваћено • Accepted:
July 20, 2017

Online first: August 1, 2017

Correspondence to:

Danielius SERAPINAS
Mykolas Romeris University
Ateities 20, Vilnius LT 08303,
Lithuania
dserapinas@gmail.com

value – were included in the study [1]. Patients with chronic or acute inflammation were excluded from the study. After an appropriate physical examination, data on the symptoms of the patient and the diagnosis of COPD was also collected. Smoking history was also calculated in pack-years as the product of tobacco use (in years) and the average number of cigarettes smoked per day / 20 (years × cig. per day / 20).

Sample collection and evaluation

Blood samples were taken in serum tubes, clotted at normal room temperature for 35–65 minutes and centrifuged for 15 minutes at 4,000 rpm. Then, the samples were frozen at -70°C for further analysis. The serum levels of AAT were determined by nephelometry using commercial kits (Dade Behring Marburg GmbH, Marburg, Germany) according to the manufacturer instructions. AAT phenotyping was carried out by means of isoelectric focusing (LKB Multiphor II and LKB Macrodrive 5 Constant Power Supply, Amersham Pharmacia Biotech, Piscataway, NJ, USA), as previously described [13]. The analysis of C-reactive protein (CRP) in serum was done using standard assays (IBL International GmbH, Hamburg, Germany).

Statistical analysis

Descriptive statistics were used to tabulate the primary cohort database. Quantitative variables were expressed as means with standard deviations. Differences of quantitative data were assessed by the Kruskal–Wallis H-test. Correlations between variables were determined by the Spearman correlation test. A p-value of less than 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Demographic descriptions of studied 1,167 COPD patients are shown in Table 1. Eighty-two percent of the patients were current (57%) or former (25%) smokers of 22.1 ± 12.2 pack-years, and 18% never smoked.

Phenotype distribution was as follows: 1,076 (92.2%) PI*MM, 40 (3.4%) PI*MZ, 39 (3.3%) PI*MS, 1 (0.1%) PI*SS, 3 (0.3%) PI*SZ, and 8 (0.7%) PI*ZZ.

The mean AAT serum level (g/l) was of 1.58 ± 0.43. As expected, we found significant differences in AAT serum concentrations between groups (p < 0.05) (Figure 1). The PI*ZZ group showed a markedly lower AAT blood level (0.40 ± 0.34) relative to the other AAT phenotype groups.

While analyzing lung function, the patients with AAT deficiency (PI*ZZ, PI*SZ, PI*SS) were grouped into one group. These individuals with severe AAT deficiency showed poorer spirometric FEV₁ (46 ± 20; p < 0.05) and FEV₁/FVC (48 ± 16; p < 0.05) values than PI*MM, PI*MS, and PI*MZ patients (Table 2).

We found a statistically significant negative correlation between the AAT concentration and the FEV₁ % predicted

Table 1. General data of study individuals

| Variable | Values* |
|----------------|---------------------|
| Age (years) | 64 ± 12 |
| Male/female | 834 (71) / 333 (29) |
| Smoking status | |
| Smokers | 660 (57) |
| Ex-smokers | 294 (25) |
| Never-smokers | 213 (18) |

*Data are presented as n (%) or mean ± SD




Figure 1. Serum alpha-1 antitrypsin (AAT) concentration in COPD patients with different AAT phenotypes

Table 2. Expression of lung function and C-reactive protein (CRP) concentration in chronic obstructive pulmonary disease (COPD) patients with different alpha-1 antitrypsin phenotypes

| Variable | MM n = 1,076 | MS n = 39 | MZ n = 40 | SS, SZ, ZZ n = 12 |
|---------------------------------------|-----------------|--------------|--------------|----------------------|
| FVC (% predicted normal) | 74 ± 19 | 75 ± 15 | 73 ± 15 | 75 ± 17 |
| FEV ₁ (% predicted normal) | 48 ± 17 | 51 ± 16 | 52 ± 18 | 46 ± 20 |
| FEV ₁ /FVC (%) | 54 ± 11 | 56 ± 11 | 57 ± 12 | 48 ± 16 |
| CRP (mg/L) | 9.6 ± 0.7 | 10.2 ± 0.8 | 11.3 ± 1.2 | 9.3 ± 1.5 |
| COPD stage | | | | |
| I | 32 (3) | 2 (5) | - | 1 (8) |
| II | 538 (50) | 21 (54) | 22 (55) | 3 (25) |
| III | 433 (40) | 12 (31) | 14 (35) | 5 (42) |
| IV | 73 (7) | 4 (10) | 4 (10) | 3 (25) |

Data are presented as n (%) or mean ± SD




Figure 2. The correlation between the AAT concentration and FEV₁ in COPD patients without AAT deficiency (Spearman correlation coefficient)

Table 3. The correlation between the alpha-1 antitrypsin concentration and FEV₁ in chronic obstructive pulmonary disease patients without alpha-1 antitrypsin deficiency according to smoking status and sex

| Patient group | n | r | Gender | n | r |
|---------------|-----|----------------------|--------|-----|----------------------|
| Smokers | 617 | -0.511 (p < 0.05) | Male | 415 | -0.407 (p < 0.05) |
| | | | Female | 202 | -0.332 (p < 0.05) |
| Ex-smokers | 249 | -0.403 (p < 0.05) | Male | 179 | -0.398 (p < 0.05) |
| | | | Female | 70 | -0.178 (p > 0.05) |
| Never-smokers | 210 | -0.211 (p > 0.05) | Male | 160 | -0.166 (p > 0.05) |
| | | | Female | 50 | -0.152 (p > 0.05) |

r – Spearman correlation coefficient

value in PI*MM phenotype ($r = -0.511$; $p < 0.05$) (Figure 2). While analyzing correlation between AAT concentration and FEV₁ in COPD patients according to smoking status and sex, we observed an inverse correlation in smokers and ex-smokers, but not in non-smokers. In males, this correlation was stronger than in females (Table 3). Patients with elevated CRP were excluded from calculations. In addition, we detected that inverse correlations between CRP and FEV₁ have also been shown in COPD patients with the PI*MM phenotype ($r = -0.583$; $p < 0.05$). However, we didn't find such a correlation in COPD patients with AAT deficiency. In patients without the AAT deficiency, a significant positive association of blood AAT and CRP levels was detected ($r = 0.667$; $p < 0.05$).

DISCUSSION

The importance of the presented data is that circulating AAT inversely correlated with FEV₁ in COPD cases without the AAT deficiency. Such relationship had also been shown with healthy individuals [14, 15]. SAPALDIA project investigated associations of circulating AAT level with lung function in the general population and detected a negative correlation of serum AAT concentration with FEV₁ [14]. The amount of AAT that passively diffuses from the serum to the lung increases during an inflammation, which may be present in COPD [16]. This may indicate the increased need of AAT production to meet requirements of overcoming the release of various endogenous enzymes from inflammatory cells in the lungs, but its protective function may be overrun by the high level of secreted proteases [17]. However other studies have not found such a relationship between the serum AAT level and FEV₁% predicted value in COPD patients [18]. Possibly many other mechanisms might also be important for the pulmonary function, and not only for the inflammatory response.

Detected low AAT level in the PI*ZZ phenotype and the FEV₁ AAT ratio association may reflect a dual role of the AAT molecule as a pulmonary disease marker. The impact of AAT on pulmonary function seems to be a conclusion of

context-dependent (i.e. AAT phenotype) and contrasting protective and proinflammatory effects in lung lining. On the one hand, elevated blood AAT level can show a beneficial shift in the antiprotease–protease balance, the center piece of the pathophysiological mechanism mediating the effect of most severe AAT deficiency on COPD. On the other hand, elevated blood AAT can also reflect low-grade inflammatory reaction in the lung [19, 20]. Significantly higher AAT concentration was even reported for AAT deficient (PI*ZZ) patients with COPD compared to PI*ZZ patients without COPD, further supporting the hypothesis that AAT concentration may also reflect an ongoing proinflammatory reaction [21]. Thus, our results support the hypothesis that the reduction of lung function may be a consequence of the presence of inflammatory stimuli.

Consistent with these findings, we could show a positive relationship between the AAT and CRP levels. High serum CRP concentrations in severe COPD individuals have been reported in other studies [5, 13, 14, 22]. Gan et al. [22] were the first to emphasize the importance of high CRP levels in COPD patients, showing the inflammatory process in even stable disease cases. Both CRP and AAT are acute-phase proteins. Several studies found CRP and AAT elevation in COPD patients, indicating that the inflammatory process is present in pathogenesis of the disease [5, 7, 21, 22, 23]. In addition, we find inverse correlations between CRP and FEV₁. Even in healthy individuals, an elevation of the CRP concentration over time was connected with a steeper FEV₁ decline [23, 24]. In these studies, FEV₁ was also inversely associated with blood CRP level. CRP reflects total systemic inflammation in many diseases and has been shown to upregulate the production of inflammatory cytokines [7]. The reasons for the inverse association between reduced lung function and systemic inflammation are not fully understood, but several mechanisms may be involved. Firstly, reduced pulmonary function may be responsible for the observed systemic inflammatory process. Inflammatory pulmonary epithelial cells have been shown to express small amounts of CRP and IL-6 [20, 25, 26]. Hence, the persistence of a systemic inflammatory process may result in damage to the airways, promoting the decline in FEV₁ in COPD patients. The data show that AAT has an immunomodulating capacity and acute increase in AAT level during various infectious and inflammatory states may enhance the magnitude of proinflammatory cells' reaction to endotoxic materials and subsequently accelerate the resolution of the inflammatory process.

CONCLUSION

We found that in patients without AAT deficiency, detected negative association of AAT level with FEV₁ and positive association with CRP level defined the importance of AAT as a biomarker of systemic inflammation for lung function in COPD. However, associations are complex and understanding the reactions of various mediators will require appropriately designed further studies.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. Executive Summary. [Accessed: July 2017] Available from: <http://goldcopd.org>.
2. Wu YQ, Shen YC, Wang H, Zhang JL, Li DD, Zhang X, et al. Serum angiopoietin-like 4 is over-expressed in COPD patients: association with pulmonary function and inflammation. *Eur Rev Med Pharmacol Sci*. 2016; 20(1):44–53.
3. Wang Y, Shumansky K, Sin DD, Man SF, Akhbar L, Connett JE, et al. Associations of interleukin-1 gene cluster polymorphisms with C-reactive protein concentration and lung function decline in smoking-induced chronic obstructive pulmonary disease. *Int J Clin Exp Pathol*. 2015; 8(10):13125–35.
4. Topic A, Prokic D, Stankovic I. Alpha-1-antitrypsin deficiency in early childhood. *Fetal Pediatr Pathol*. 2011; 30(5):312–9.
5. López-Sánchez M, Muñoz-Esquerre M, Huertas D, Montes A, Molina-Molina M, Manresa F, et al. Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction. *Clin Respir J*. 2017; 11(6):859–66.
6. Wannamethee SG, Shaper AG, Papacosta O, Lennon L, Welsh P, Whincup PH. Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men – the British Regional Heart Study. *Thorax*. 2016; 71(6):526–34.
7. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. *Eur J Intern Med*. 2008; 19(2):104–8.
8. Bradley WP, Boyer MA, Nguyen HT, Birdwell LD, Yu J, Ribeiro JM, et al. Primary role for TLR-driven TNF rather than cytosolic immune detection in restricting *Coxiella burnetii* phase II replication within mouse macrophages. *Infect Immun*. 2016; 84(4):998–1015.
9. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003; 168(7):818–900.
10. Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. *Ther Adv Respir Dis*. 2016; 10(1):72–84.
11. Arias P, Kerner J, Christofferson M, Berquist W, Park KT. Misdiagnosis of α -1 antitrypsin phenotype in an infant with CMV infection and liver failure. *Dig Dis Sci*. 2014; 59(8):1710–3.
12. Wright TK, Gibson PG, Simpson JL, McDonald VM, Wood LG, Baines KJ. Neutrophil extracellular traps are associated with inflammation in chronic airway disease. *Respirology*. 2016; 21(3):467–75.
13. Pierce JA, Eradio BG. Improved identification of antitrypsin phenotypes through isoelectric focusing with dithioerythritol. *J Lab Clin Med*. 1979; 94(6):826–31.
14. Garcia-Rio F, Miravittles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. *Respir Res*. 2010; 11:63.
15. Senn O, Russi EW, Schindler C, Imboden M, von Eckardstein A, Brändli O, et al. Circulating alpha1-antitrypsin in the general population: determinants and association with lung function. *Respir Res*. 2008; 25:9:35.
16. Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. *Ther Adv Respir Dis*. 2016; 10(1):72–84.
17. Lomas DA. Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency. *COPD*. 2013; 10 Suppl 1:17–25.
18. Higashimoto Y, Yamagata Y, Taya S, lwata T, Okada M, Ishiguchi T, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences. *Respirology*. 2008; 13(1):128–33.
19. Meyer KC, Rosenthal NS, Soergel P, Peterson K. Neutrophils and low-grade inflammation in the seemingly normal aging human lung. *Mech Ageing Dev*. 1998; 104(2):169–81.
20. Wei J, Xiong XF, Lin YH, Zheng BX, Cheng DY. Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. *PeerJ*. 2015; 3:e1199.
21. Welle I, Bakke PS, Eide GE, Fagerhol MK, Omenaas E, Gulsvik A. Increased circulating levels of alpha1-antitrypsin and calprotectin are associated with reduced gas diffusion in the lungs. *Eur Respir J*. 2001; 17(6):1105–11.
22. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax*. 2004; 59(7):574–80.
23. Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. *Respir Med*. 2006; 100(12):2112–20.
24. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. *Thorax*. 2004; 59(10):892–6.
25. Jane M, Gould, Jeffrey N. Weiser. Expression of C-reactive protein in the human respiratory tract. *Infect Immun*. 2001; 69(3):1747–54.
26. Lopez-Campos JL, Calero-Acuña C, Lopez-Ramirez C, Abad-Arriaza M, Márquez-Martín E, Ortega-Ruiz F, et al. Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease. *Biomark Med*. 2016; 10(2):109–22.

Повезаност нивоа алфа-1 антитрипсина и плућне функције код болесника са хроничном опструктивном болешћу плућа

Данијелијус Серапинас¹, Рута Нутаутијене², Рута Пукинскаите¹, Даива Барткевицијене³, Диана Баркаускијене⁴, Раимундас Сакалаускас⁴

¹Универзитет „Миколас Ромерис“, Вилњус, Литванија;

²Државна болница Каунас, Каунас, Литванија;

³Универзитет у Вилњусу, Медицински факултет, Катедра за акушерство и гинекологију, Вилњус, Литванија;

⁴Литвански универзитет здравствених наука, Одељење за пулмонологију и имунологију, Каунас, Литванија

САЖЕТАК

Увод/Циљ Недостатак алфа-1 антитрипсина је добро познат наслеђен фактор ризика за хроничну опструктивну болест плућа (ХОБП). Међутим, низак ниво алфа-1 антитрипсина може узроковати различита смањења плућних функција.

Циљ нашег рада био је да се процени могућа повезаност нивоа алфа-1 антитрипсина и плућне функције код болесника с ХОБП са разним фенотипама алфа-1 антитрипсина.

Методе Концентрација серумског алфа-1 антитрипсина код болесника са ХОБП ($n = 1167$) у складу с критеријумима GOLD анализирана је коришћењем нефилометрије, а фенотип алфа-1 антитрипсина одређен је изолелеккричним фокусирањем.

Резултати Код ХОБП болесника без недостатка алфа-1 антитрипсина (ММ) пронађена је значајна негативна повезаност плућне функције (FEV_1) са серумом алфа-1 антитрипсина ($r = -0,511$, $p < 0,05$) и концентрацијом ЦРП ($r = -0,583$, $p < 0,05$); осим тога, ниво алфа-1 био је у позитивној повезаности са концентрацијом ЦРП ($r = 0,667$, $p < 0,05$).

Закључак Код ХОБП болесника без недостатка алфа-1 антитрипсина пронађена је значајна негативна повезаност са FEV_1 и позитивна повезаност са нивоом ЦРП доказала је значај алфа-1 антитрипсина као показатеља системске инфламације.

Кључне речи: хронична опструктивна болест плућа; алфа-1 антитрипсин; функција плућа